Statements (79)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Alder_Bio_Pharmaceuticals
|
| gptkbp:advocacy |
engaged with patient groups
|
| gptkbp:awards |
various industry awards
|
| gptkbp:benefits |
competitive packages offered
|
| gptkbp:business_model |
committed to ethical research practices
|
| gptkbp:ceo |
gptkb:Mihael_H._Polymeropoulos
|
| gptkbp:clinical_trial |
published in peer-reviewed journals
multiple ongoing clinical trials monitored for effectiveness shared with the public across multiple countries secured from investors focused on unmet medical needs focus on innovative treatments Phase I for new compounds Phase II for Tasimelteon Phase III for Hetlioz focused on diverse populations |
| gptkbp:clinical_trial_ethics |
adhered to strict guidelines
|
| gptkbp:collaboration |
with various healthcare organizations
|
| gptkbp:collaborations |
with biotech firms
with leading universities |
| gptkbp:community_engagement |
active in community outreach
|
| gptkbp:community_support |
involved in local health initiatives
|
| gptkbp:conducts_research_on |
gptkb:Dr._John_Doe
|
| gptkbp:drug_safety |
prioritized in all developments
|
| gptkbp:economic_impact |
into new regions
|
| gptkbp:financial_reports |
published quarterly
|
| gptkbp:financial_support |
available for patients
for research initiatives |
| gptkbp:focus |
development of therapies for central nervous system disorders
|
| gptkbp:founded |
gptkb:2003
|
| gptkbp:funding |
secured from various sources
|
| gptkbp:global_presence |
operates internationally
|
| gptkbp:grants |
awarded for innovative projects
|
| gptkbp:has_advisory_board |
comprised of industry experts
|
| gptkbp:head_of_clinical_trials |
gptkb:Dr._Jane_Smith
|
| gptkbp:headquarters |
gptkb:Washington,_D._C.
|
| gptkbp:healthcare |
aims for breakthrough therapies
driving advancements in treatment. received for multiple products |
| https://www.w3.org/2000/01/rdf-schema#label |
Vanda Pharmaceuticals Ltd.
|
| gptkbp:instruction_set |
diverse product pipeline
|
| gptkbp:invention |
multiple patents granted
|
| gptkbp:investment |
available online
conducted regularly in research and development |
| gptkbp:investment_strategy |
monitored by analysts
|
| gptkbp:investor_meetings |
held annually
|
| gptkbp:market |
conducted regularly
|
| gptkbp:market_cap |
approximately $500 million
|
| gptkbp:market_launch |
planned for upcoming years
|
| gptkbp:notable_products |
gptkb:Fanapt
gptkb:Hetlioz Tasimelteon |
| gptkbp:number_of_employees |
approximately 100
|
| gptkbp:partnership |
various academic institutions
|
| gptkbp:partnerships |
with hospitals and clinics
with other pharmaceutical companies |
| gptkbp:patient_education |
provided through various channels
|
| gptkbp:publications |
contributed to numerous studies
|
| gptkbp:regulatory_compliance |
submitted to health authorities
FDA approval for Fanapt FDA approval for Hetlioz |
| gptkbp:research_areas |
neurology
psychiatry |
| gptkbp:research_focus |
rare diseases
schizophrenia sleep disorders |
| gptkbp:revenue |
approximately $100 million
|
| gptkbp:social_responsibility |
committed to ethical practices
|
| gptkbp:stock_exchange |
publicly traded
|
| gptkbp:stock_symbol |
VNDA
|
| gptkbp:subsidiary |
Vanda Pharmaceuticals, Inc.
|
| gptkbp:sustainability_initiatives |
implemented in operations
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:training |
ongoing professional development programs
|
| gptkbp:website |
www.vandapharma.com
|